Title: A Study on Correlation of Peripheral Neuropathy in Patients Receiving Atorvastatin Therapy- A Study in North Bihar
Authors: Dr Umesh Chandra Jha, Dr Rajeev Kumar, Dr Ashish Narayan
DOI: https://dx.doi.org/10.18535/jmscr/v5i10.60
Abstract
The role of statins to reduce risks of vascular death, non fatal myocardial infarction and stroke, is well established. STATIN competitively inhibit enzyme HMG-CoA reductase which convert HMG-CoA to mevalonate. Atorvastatin the most popular statin is more potent and appears to have the highest LDL-CH lowering efficacy. There are several case reports of statin induced peripheral neuropathy. The aim of the study is to find a correlation of development of peripheral neuropathy in patients receiving atorvastatin.
Methods: Patients (age >30years, both gender) attending outdoor clinic and indoor patients of Medicine department darbhanga medical college were selected by simple random method taking atorvastatin for different indications, dosages and duration. The statistical significance of development of peripheral neuropathy was measured.
Results: There was development of peripheral neuropathy in about 26% individuals receiving atorvastatin therapy. Seven males and six females developed neuropathy out of total 29 and 21 respectively. Out of total 50 individuals 20 was free from any co-morbidity. Only 2 out of 20 developed peripheral neuropathy. Patient having only diabetes as co-morbidity was 10 and out of that 3 developed peripheral neuropathy. Individual having both diabetes and dyslipidemia were 11 and among them 2 developed peripheral neuropathy. And patients having diabetes, dyslipidemia and hypertension was 9 and 6 developed neuropathy.
Conclusion: A substantial proportion of patients taking atorvastatin have peripheral neuropathy (26%).It was observed that neuropathy in patients taking statins does not depend on sex. Diabetes, dyslipidemia and hypertension as a co-morbidity increases the risk of neuropathy in atorvastatin users. Statin induced neuropathy or neuropathy where statin is the only implicating factor is less common than diabetic or other neuropathies.
References
- Naci H, Brugts J & Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circulation Cardiova-scular Quality and Outcomes2013;6:390–399.
- Armitage J. The safety of statins in clinical practice. Lancet2007;370:1781–1790.
- Mancini GB, Baker S, Bergeron J et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol2011;27:635–662.
- Otruba P, Kanovsky P, Hlustik P. Treatment with statins and peripheral neuropathy: results Of 36-months a prospective clinical and neurophysio-logical follow-up. Department of Neurology, Palacky University Medical School, University Hospital, Olomouc, Czech Republic.
- Erik S. Stroes1*, Paul D. Thompson2, Alberto Corsini3. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. A clinical update.
- Stock J. Statin-associated muscle symp-toms EAS Consensus Panel paper focuses on this neglected patient group. Atheroscl-erosis2015;242:346–350.
- Folkers K, Langsjoen P, Willis R et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA1990;87:8931–8934.
- Schirris TJ, Renkema GH, Ritschel T et al. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metab2015;22:399–407.
- Dirks AJ & Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol2006;291:C1208–C1212.
- Cohen JD, Brinton EA, Ito MK et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012;6:208–215.